Syneos Health (SYNH) Stock Price
Syneos Health Price
Over the last 11 years Syneos Health grew revenue by 21.1% annually, reaching 5.39 B USD. Earnings per share have grown at 3.6% per year over the last 7 years. For Syneos Health, the net margin of 4.9% is up versus 0.6% a few years ago.
Syneos Health stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Syneos Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Syneos Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Syneos Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Syneos Health Price |
|---|
Syneos Health Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Syneos Health Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.87 | 1.00 | 1.18 | 1.40 | 1.61 | 2.67 | 4.39 | 4.68 | 4.42 | 5.21 | 5.39 | 5.14 | 5.25 | 5.60 | 5.69 | 5.91 |
| 32.52 | 14.63 | 18.39 | 18.76 | 15.08 | 65.96 | 64.30 | 6.49 | -5.56 | 18.05 | 3.47 | -4.78 | 2.14 | 6.73 | 1.55 | 3.94 |
| 21.89 | 22.11 | 24.96 | 26.59 | 25.03 | 23.20 | 21.75 | 22.01 | 23.04 | 23.37 | 23.25 | 23.25 | 23.25 | 23.25 | 23.25 | 23.25 |
| 0.19 | 0.22 | 0.29 | 0.37 | 0.40 | 0.62 | 0.96 | 1.03 | 1.02 | 1.22 | 1.25 | 1.19 | 1.22 | 1.30 | 1.32 | 1.37 |
| -37.00 | 31.00 | 63.00 | 152.00 | 155.00 | -28.00 | 307.00 | 324.00 | 293.00 | 389.00 | 403.00 | 608.00 | 690.00 | 741.00 | 831.00 | 914.00 |
| -4.26 | 3.12 | 5.35 | 10.86 | 9.63 | -1.05 | 6.99 | 6.93 | 6.64 | 7.46 | 7.47 | 11.84 | 13.16 | 13.24 | 14.62 | 15.47 |
| -59.00 | -41.00 | -23.00 | 117.00 | 112.00 | -138.00 | 24.00 | 131.00 | 192.00 | 234.00 | 266.00 | 355.00 | 405.00 | 470.00 | 506.00 | 571.00 |
| – | -30.51 | -43.90 | -608.70 | -4.27 | -223.21 | -117.39 | 445.83 | 46.56 | 21.88 | 13.68 | 33.46 | 14.08 | 16.05 | 7.66 | 12.85 |
| 52.00 | 51.90 | 57.50 | 58.01 | 54.93 | 104.36 | 104.82 | 105.38 | 105.41 | 105.00 | 103.22 | 103.22 | 103.22 | 103.22 | 103.22 | 103.22 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Syneos Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Syneos Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Syneos Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Syneos Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Syneos Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Syneos Health stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Syneos Health Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Syneos Health business model & stock analysis
Syneos Health SWOT Analysis
Strengths
- Syneos Health Inc is a leading global provider of integrated commercialization and clinical research solutions.
- The company has a strong reputation in the industry and a wide network of clients and partners.
- Syneos Health Inc offers a comprehensive range of services, including clinical development, strategic consulting, and commercialization services, providing clients with end-to-end solutions.
- The company's experienced and skilled workforce is a valuable asset, contributing to its ability to deliver high-quality services.
Weaknesses
- Syneos Health Inc operates in a highly competitive market, facing intense competition from other major players in the industry.
- The company's dependence on a few large clients may pose risks, particularly if any of these clients reduce or terminate their business with Syneos Health Inc.
- The complexity of the services offered by Syneos Health Inc requires continuous investment in training and development, which could strain the company's resources.
- Regulatory changes and evolving industry standards can affect the company's operations and require adaptability to stay competitive.
Opportunities
- The increasing demand for pharmaceutical and healthcare services globally presents significant growth opportunities for Syneos Health Inc.
- The emerging markets, such as Asia and Latin America, offer untapped potential for expansion and market penetration.
- Technological advancements, such as digital health solutions and remote clinical trials, create new avenues for Syneos Health Inc to innovate and differentiate itself.
- Collaborations and partnerships with pharmaceutical companies, research organizations, and healthcare providers can enhance Syneos Health Inc's market presence and service offerings.
Threats
- Economic fluctuations and geopolitical uncertainties can impact the demand for pharmaceutical and healthcare services, potentially affecting Syneos Health Inc's business.
- Pricing pressures from clients and payers may reduce profit margins and impact the company's financial performance.
- Stringent regulations and compliance requirements in the healthcare industry can increase operational costs and restrict market access.
- The constant need to invest in technology and infrastructure to stay competitive can be financially challenging for Syneos Health Inc.
Syneos Health Segments
Syneos Health Revenue by Segment
3 Years
5 Years
Max
Details
Syneos Health Revenue by Region
3 Years
5 Years
Max
Details
Syneos Health Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Syneos Health historical P/E ratio, EBIT multiple, and P/S ratio
Syneos Health annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Syneos Health shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Syneos Health Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/8/2024 | 0.92USD | 1.34 BUSD | 2024 Q1 |
| 2/14/2024 | 0.99USD | 1.30 BUSD | 2023 Q4 |
| 7/31/2023 | 0.99USD | 1.28 BUSD | 2023 Q2 |
| 4/27/2023 | 0.88USD | 1.27 BUSD | 2023 Q1 |
| 2/15/2023 | 1.23USD | 1.32 BUSD | 2022 Q4 |
| 11/4/2022 | 1.34USD | 1.39 BUSD | 2022 Q3 |
| 8/2/2022 | 1.22USD | 1.41 BUSD | 2022 Q2 |
| 4/29/2022 | 0.97USD | 1.34 BUSD | 2022 Q1 |
| 2/17/2022 | 1.46USD | 1.43 BUSD | 2021 Q4 |
| 11/3/2021 | 1.19USD | 1.36 BUSD | 2021 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Syneos Health stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Syneos Health shareholder structure
| % | Name |
|---|---|
9.93527% | |
9.54835% | |
9.34939% | |
4.00680% | |
3.60908% | |
3.51299% |
Syneos Health Executives and Management Board
Ms. Michelle Keefe
(56)Chief Executive Officer, Director · since 2017
Mr. Michael Brooks
(49)Chief Operating Officer
Mr. Jonathan Olefson
(47)General Counsel, Corporate Secretary
Mr. Christian Tucat
(53)Chief Business Officer
Mr. John Dineen
(59)Non-Executive Independent Chairman of the Board
Syneos Health Supply Chain
Syneos Health Supply Chain
Correlation: how closely stock prices move together
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | 0.51 | 0.06 | -0.33 | -0.10 | 0.79 | ||
| 2 | -0.14 | -0.10 | 0.78 | 0.64 | 0.75 | ||
| 3 | 0.70 | 0.87 | 0.68 | 0.38 | 0.69 | ||
| 4 | -0.13 | 0.48 | 0.86 | 0.32 | 0.67 | ||
| 5 | 0.49 | 0.12 | 0.46 | -0.10 | 0.60 |
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | 0.64 | 0.65 | 0.91 | 0.86 | — | ||
| 2 | 0.58 | 0.42 | 0.87 | — | — | ||
| 3 | 0.38 | 0.80 | -0.11 | 0.03 | — | ||
| 4 | 0.40 | 0.09 | -0.62 | -0.40 | -0.73 | ||
| 5 | 0.43 | 0.72 | 0.93 | 0.49 | -0.70 |
Frequently asked questions about Syneos Health
Syneos Health Inc operates as a leading global contract research organization (CRO) that provides integrated solutions to the pharmaceutical and biotechnology industries. The company offers a comprehensive range of services, including clinical development, commercialization, and consulting, aimed at accelerating the delivery of innovative therapies to patients. Syneos Health's business model focuses on leveraging its expertise, technology, and extensive network of resources to support clients in bringing new drugs and treatments to market efficiently. By combining clinical and commercial insights, the company aims to streamline the drug development process and improve the overall success rate for its clients. Syneos Health Inc is committed to revolutionizing the clinical research industry and advancing healthcare outcomes globally.
Syneos Health stock
Syneos Health Peer Group
Syneos Health Ticker
Syneos Health FIGI
All fundamentals and in-depth analysis of Syneos Health
Our stock analysis for Syneos Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Syneos Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.